The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 28, 2020

Filed:

Jun. 02, 2015
Applicants:

Boston Medical Center Corporation, Boston, MA (US);

Trustees of Boston University, Boston, MA (US);

Inventors:

George J. Murphy, Boston, MA (US);

David H. Sherr, West Roxbury, MA (US);

Sarah S. Rozelle, Jamaica Plain, MA (US);

Brenden W. Smith, Warwick, RI (US);

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 35/00 (2006.01); C12N 5/0789 (2010.01); C12N 5/078 (2010.01); A61K 35/18 (2015.01); A61K 35/19 (2015.01); A61K 31/404 (2006.01); G01N 33/50 (2006.01); A61K 45/06 (2006.01); A61K 31/655 (2006.01); G01N 33/80 (2006.01); G01N 33/86 (2006.01); A61K 35/12 (2015.01);
U.S. Cl.
CPC ...
C12N 5/0647 (2013.01); A61K 31/404 (2013.01); A61K 31/655 (2013.01); A61K 35/18 (2013.01); A61K 35/19 (2013.01); A61K 45/06 (2013.01); C12N 5/0641 (2013.01); C12N 5/0644 (2013.01); G01N 33/5044 (2013.01); G01N 33/80 (2013.01); G01N 33/86 (2013.01); A61K 2035/124 (2013.01); C12N 2501/60 (2013.01); C12N 2501/998 (2013.01); C12N 2501/999 (2013.01); C12N 2506/03 (2013.01); C12N 2506/45 (2013.01); G01N 2500/10 (2013.01);
Abstract

This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (MEP), comprising differentiating a stem cell into a MEP in culture in the presence of an aryl hydrocarbon receptor (AhR) agonist. In some embodiments the stem cell is a pluripotent stem cell. In some embodiments the MEP co-expresses CD41 and CD235. In some embodiments the number of MEPs produced in the culture increases exponentially. Methods of making a red blood cell (RBC) by culturing a MEP in the presence of an AhR agonist are also provided. Methods of making a megakaryocyte and/or a platelet, comprising culturing a MEP in the presence of an AhR modulator are also provided. In some embodiments the AhR modulator is an AhR antagonist. This disclosure also provides compositions comprising at least 1 million MEPs per ml and compositions in which at least 50% of the cells are MEPs.


Find Patent Forward Citations

Loading…